AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2015
Feb 17, 2015
30591_dirs_2015-02-17_4906c668-63a9-4d55-8fab-8c045c143c69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2015-02-12
Reporting Person: WENDER JOSEPH H (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-02-12 | Common Stock | M | 10000 | $3.95 | Acquired | 47217 | Indirect |
| 2015-02-12 | Common Stock | S | 10000 | $62.146 | Disposed | 37217 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-02-12 | Non-Employee Director Stock Option (right to buy) | $3.95 | M | 10000 | Disposed | 2015-06-30 | Common Stock (10000) | Indirect |
Footnotes
F1: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2015.
F2: The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.960 to $62.325, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.